price feb usd
focu guidanc misplac
what new solid beat mix guidanc near-term focu remain
top- bottom-lin beat underscor strength
commerci organ underwhelm outlook reect impact
on-going clinic studi previous appreci
street manag reiter demand remain strong core
pnh/ahu market initi comment mg like reect conservat
instead point pivot data next quarter key driver
stock henc remain bullish see deep dive
guidanc reect relat headwind think
clinical/commerci dynam normal post-approv growth outlook
acceler clinic trial patient translat revenu inde
includ impact patient next year guidanc
growth outlook remain dierenti even conservat around mg
launch overal view top pick larg cap biotech reiter
buy rate
strong quarter line alexion report total sale
top consensu expect vs dbe vs
street beat larg driven primarili volum growth across
product overal strensiq kanuma soliri
modestli oset price headwind fx geograph
row segment show strongest growth absolut
rel term versu third quarter vs ep
vs dbe vs street reect save restructur
initi ultim take account impact on-going
clinic program well price fx headwind
result underscor strength underli franchis
guidanc lower end expect mostli reflect
time note top-lin guidanc still in-lin recent
state nancial ambit double-digit growth rang given impli yoy
growth reect guidanc
impact on-going competitor studi assum
biggest driver well price pressur also
like recur theme level importantli note
market headwind like slow
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
impact top-lin provid better comp
pnh read-out next big catalyst upsid driver
quarterli result guidanc unsurprisingli
core focu earn call note upcom pivot readout
program overwhelmingli biggest driver
share recal recent publish deep dive
remain bullish ahead data condent ahead
read-out also see highli favor risk-skew current level
today call manag reiter belief demonstr
non-inferior would consid success although believ
investor also look potenti statist numer trend
favor help fulli understand prole
mg launch also remain key focu manag remain
confid util uptak soliri gmg robust
patient vs patient one month ago base
guidanc believ estim could conserv note
recent growth patient may somewhat distort due patient
wait enrol ie would need go process twice
start late expect revenu start ramp
although launch dynam provid continu
bullish program import growth driver compani
notabl compani broadli outlin initi nancial ambit
program potenti rst year revenu
pipelin readout nmo drive upsid
posit pipelin focu undoubtedli
pivot studi also highlight prevent trial
soliri nmo anoth potenti revenu driver manag
continu frame high risk studi see reason believ
may read-out posit reect current expect
stock trade inde impress event reduct
observ small open label studi month
treatment although less clear how/if eect maintain
longer period given low expect potenti signic
market size refractori nmo patient also see favor risk-skew
ahead readout beyond nmo compani also plan pursu
increment bd part pipelin stori go forward although
everyth second term prioriti potenti
potenti de-risk ip updat mention call
manag expect give updat statu eu patent
inde strong ip defens would augment oensiv defens
provid biosimilar risk would
drive potenti bear these increment de-risk stock
manag highlight european ip strategi mirror success
applic us japan could minim potenti
biosimilar headwind inde believ prove
clinic dierenti includ dose prole believ
combin treatment option lack biosimilar price
headwind would reect best-cas scenario impli
meaning upsid current level
chang model
updat model follow result well incorpor
guidanc commentari around expect price headwind
expect tax rate go forward continu impact soliri sale
on-going trial specic although expect outlier
term price pressur also reect moder price pressur
beyond addit increas tax rate estim
beyond prior given new guidanc expect tax rate
addit given manag commentari around dynam impact
on-going trial soliri ie headwind continu
approv time patient would transit commerci drug
incorpor step-up revenu account
dynam overal revenue/ep estim decreas
slightli adjust price target
forecast ratio
figur result chang model
actualdbconsensusactualdbconsensusdb newdb oldconsensusguidancerevenuessoliri metabol product expensescost income/expensesinterest incom tax share februari
price current end previou trade session unless otherwis indic sourc local exchang via reuter bloomberg vendor
inform sourc deutsch bank subject compani sourc disclosur pertain recommend estim made secur
primari subject research pleas see recent publish compani report visit global disclosur look-up page websit http //gm db com/ger/disclosure/
disclosuredirectori eqsr asid within report import conict disclosur also found http //gm db com/equ disclosur lookup legal
tab investor strongli encourag review inform invest
import disclosur requir regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
deutsch bank and/or aliat make market equiti secur issu compani
deutsch bank and/or aliat expect receiv intend seek compens invest bank
servic compani next three month
deutsch bank and/or aliat receiv non-invest bank relat compens
compani within past year
compani client deutsch bank secur inc within past year time
import disclosur requir non-u regul
disclosur mark asterisk may also requir least one jurisdict addit unit state see
import disclosur requir non-u regul explanatori note
deutsch bank and/or aliat make market equiti secur issu compani
disclosur pertain recommend estim made secur primari subject
